Modality
Gene Editing
MOA
TROP-2 ADC
Target
FXIa
Pathway
Autophagy
GBM
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
Oct 2018
→ Aug 2029
Phase 2Current
NCT08442926
1,560 pts·GBM
2018-10→2029-08·Terminated
1,560 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-08-113.4y awayPh2 Data· GBM
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2
Termina…
Catalysts
Ph2 Data
2029-08-11 · 3.4y away
GBM
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08442926 | Phase 2 | GBM | Terminated | 1560 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| BII-5449 | Biogen | Phase 3 | FXIa |